Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company’s lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada.
Metrics to compare | RVXCF | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRVXCFPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.1x | −2.9x | −0.5x | |
PEG Ratio | 0.08 | −0.04 | 0.00 | |
Price/Book | −0.5x | −0.6x | 2.6x | |
Price / LTM Sales | - | 6.5x | 3.2x | |
Upside (Analyst Target) | - | 275.0% | 40.5% | |
Fair Value Upside | Unlock | 4.4% | 4.4% | Unlock |